A case of Langerhans' cell histiocytosis following Hodgkin's disease

Introduction

Langerhans' cell histiocytosis (LCH) is a group of disorders in various tissues characterized by the proliferation of Langerhans cells, and its etiopathogenesis is unknown. Although LCH has been known for approximately a century, its etiology has yet to be elucidated. It is rarely observed in adults (1). Langerhans cells are dendritic cells that express cluster of differentiation 1a (CD1a) and S100 protein, and contain Birbeck granules. One possible etiological cause is a reactive proliferation of Langerhans cells following chemotherapy or radiotherapy for Hodgkin's disease (HD). Eosinophilic granuloma is the benign accumulation of histiocytes located primarily in the bones, but which also affects other organs, including the skin, lungs and lymph nodes. A number of cases of LCH associated with malignant lymphoma have been reported previously: It may follow after the malignant lymphoma (2–8) or occur with it (9). However, fewer cases have been reported in which LCH followed after Hodgkin's lymphoma (HL). In the present report, we present one case patient who was diagnosed with HD following chemotherapy for LCH.

Case report

Diagnosis of LCH

In March 2013, a 31-year-old man presented with a one year history of fever, pruritus and left flank bone pain. The patient's medical history indicated no abnormalities. He was referred to another clinic hospital for an assessment of the flank bone diseases. Computed tomographic (CT) scans of the left flank bone revealed a bone-destructive lesion. The patient underwent surgery to obtain a diagnosis and to excise the destructive bone. The tissue that was removed during surgery exhibited a histiocytic cell population, intermixed with eosinophils, neutrophils, multinuclear giant cells and foamy macrophages, which were observed in the background. In addition, certain fibrotic bands existed in this background. The histiocytic cells were positive for CD1a and CD30 marker proteins, as revealed by immunohistochemistry staining. However, S100 as a marker was not available for immunohistochemical analysis (Fig. 1). On the basis of the morphology and immunohistochemical staining profiles, the patient was diagnosed with LCH. The patient's treatment commenced with analgesia, and clinical remission was achieved.

Figure 1. (A) Diffuse infiltrate by the Langerhans cells (large cells with eosinophilic cytoplasm, reniform nucleus and evident nucleoli), permeated by lymphocytes, neutrophils and eosinophils (hematoxylin and eosin staining; magnification, ×400). (B) The Langerhans cells stained positively with CD1a on immunohistochemistical staining (magnification, ×400). (C) The Langerhans cells stained positively with CD30 on immunohistochemistry staining (magnification, ×400).

In June 2013, the patient presented to The First Central Hospital of Tianjin (Tianjin, China) with two sides of flank bone pain and pruritus, which had been apparent for one week. Upon admission, a physical examination revealed a rash on his epipodites. Neither peripheral lymphadenopathy nor hepatosplenomegaly were detected. The patient had no other B symptoms. The laboratory tests revealed normal levels of the blood cell count, C reactive protein, lactate dehydrogenase, hepatic and renal functions. The results of bone marrow aspirate examination, biopsy and flow cytometric analysis were normal. CT scans of the thorax and abdomen revealed lymph nodes and a large mass in the anterior and middle mediastinum (Fig. 2). A magnetic resonance imaging scan demonstrated the destroyed sclerotin in the left flank bone and two sides of the acetabular bones, and soft tissue in the left articulatio sacroiliaca. The anterior mediastinum biopsy by CT-guided needle puncture revealed the presence of lymphocytes, epithelial cell nests (cytokeratin-positive), fibrous tissue and adipose tissue, indicating thoracic gland tissue.

Figure 2. Computed tomographic scans of the thorax and abdomen, revealing the lymph nodes and a large mass in anterior and middle mediastinum.

As previously, the patient was diagnosed with LCH and treated with a combination of chemotherapeutic agents in two cycles of cyclophosphamide, vincristine and prednisolone (COP). However, the bone pain and fever continued. A CT scan of the thorax revealed that the tumor mass in the mediastinum was unchanged. Subsequently, the patient was treated with a combination of various chemotherapeutic agents in two cycles of cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). The patient went into remission as far as the bone pain and fever were concerned, and the CT scan of the thorax revealed a marked reduction in the size of the tumor mass in the mediastinum. Following six cycles of treatment with CHOP as a maintenance therapy, the patient achieved a successful clinical remission.

Diagnosis of HD

One year after the patient entered clinical remission, the patient once again developed bone pain and fever. A physical examination revealed peripheral lymph node enlargement, although no hepatosplenomegaly. The laboratory tests were normal, as identified previously. CT scans of the thorax and abdomen revealed augmentation of the tumor mass in the mediastinum. An excisional biopsy of the right inguinal lymph node was performed. Microscopic examination revealed that the atypical cells were either mononucleated or binucleated, composed of lymphocytes, plasma cells and a few eosinophils. Immunohistochemical staining revealed CD30- and CD15-positive cells. Immunostaining for CD1a protein was positive, as determined previously (Fig. 3). The patient was diagnosed with nodular sclerosing HD (stage IIIA, with spleen involvement), secondary to LCH. Subsequently, the patient was treated with a combination of various chemotherapeutic agents of adriamycin, bleomycin, vinblastine and dacarbazine (ABVD). The patient received four cycles of ABVD chemotherapy. Following the chemotherapy, the patient obtained a remission of the bone pain, fever and pruritus, and a whole-body positron emission tomographic (PET) CT scan revealed a decrease in the tumor mass in the mediastinum (Fig. 4). To date, the patient remains in treatment, and the prognosis has yet to be fully determined.

Figure 3. (A) RS cells in a background of a mixed cellularity composed of lymphocytes, plasma cells and a few eosinophils (hematoxylin and eosin staining; magnification, ×400). (B) RS cells stained positively with CD1a on immunohistochemical staining. (C) RS cells stained positively with CD30 on immunohistochemical staining. RS, Reed-Sternberg.

Figure 4. (A) FDG PET/CT scan, revealing a high FDG uptake around the left lilac crest. Other areas that revealed a high FDG uptake included the neck, glutes, left side of the pelvis and bilateral inguinal. (B) FDG PET/CT scan, revealing a high FDG uptake in mediastinal lymph nodes, although they were reduced compared with the previous assessment. FDG, fluorodeoxyglucose; PET, positron emission tomographic; CT, computed tomographic.

Discussion

LCH is a group of disorders, with the proliferation of Langerhans cells accumulating in various tissues. LCH is a rare disease that may occur at any age (10). Due to having identical clinicopathological features, it is a group of disorders characterized by a clonal neoplastic proliferation of Langerhans-type cells that express CD1a, langerin and S100 protein, and show evidence of Birbeck granules on ultrastructural examination. LCH is also known as a histiocytosis X, a term proposed by Lichtenstein in 1953 (11). It has been classified into three clinical variants: Eosinophilic granuloma, Hand-Schüller-Christian disease and Letterer-Siwe disease (12). Most organs or systems of the body may be affected, however, the skeleton, skin and pituitary are involved more frequently. Other organs involved are the liver, spleen, lymph nodes, lungs, the hematopoietic system and mucocutaneous tissues, and the central nervous system.

The etiology of LCH remains unknown, although viral causes, reactive immunological responses and genetic factors have been suggested (4). However, the progressive characteristics of the disease and its response to cancer therapies depict its neoplastic nature (13). An association between LCH and a variety of other tumor types has been recognized, and LCH has been described in association with a variety of other tumor types. The malignancies may precede, occur concurrently with, or follow the diagnosis of LCH. The most common associations are with malignant lymphoma and acute lymphoblastic leukemia (ALL) (14). Lymphoma and ALL more often occur prior to the diagnosis of LCH, although they may be diagnosed within 5 years following LCH (15). Solid tumors may occur concurrently, or follow the diagnosis of LCH. Most of those that followed LCH developed in a previous radiation field. The association between tumor formation and LCH has yet to be fully elucidated. Shin et al (16) discussed the association between the conditions of LCH and HD, and proposed various possibilities: i) HD induces LCH; ii) radiotherapy and/or chemotherapy for HD leads to the development of LCH; iii) LCH may represent a specific cell-mediated immune response to HD; and iv) a common etiological agent induces HD and LCH.

Egeler et al (15) reported their experience of 39 patients with LCH and malignant neoplasia. That study revealed that there was an association between the two conditions. A total of 25 patients were diagnosed with LCH and HL. The conclusion was that LCH is associated with lymphoma. In certain cases, histological examination revealed lymphoid cells and Langerhans cells in the same lymph node. Furthermore, the year-long interval between the development of LCH and HL suggested an association between the two diseases that is independent of chemotherapy or radiation treatments. Such an association may involve a malignant change, or modulation of the monocyte-histiocyte system. For example, Langerhans cells may themselves be premalignant, or may provide an immunological environment conducive to the development, growth and promotion of malignant cells.

In the present case study, the patient was diagnosed with LCH on the first occasion, although it was regrettable that multiple lymph nodes were observed in the mediastinum at that time, located in the anterior mediastinum and the middle mediastinum. Effective pathological tissues could not be obtained by fine needle aspiration, and the damage was too extensive for chest surgery, so no pathology was performed on the lymph node. The patient was treated with COP and CHOP chemotherapy. The B symptoms were controlled, and the diameter of the mediastina lymph nodes was reduced. A retrospective analysis determined that the COP and CHOP chemotherapies were not an effective treatment for HL; however, the B symptoms of the patient were controlled and the diameter of the lymph nodes was reduced. Perhaps at that time, HD may not have appeared. One year later, the right inguinal lymph node was observed to be enlarged in the patient. The diagnosis of HD was confirmed by a pathological biopsy of the lymph node. Following six cycles of ABVD, a PET CT scan revealed a decrease in tumor mass in the mediastinum. However, it was difficult to identify LCH and HD from a PET CT scan (17,18), therefore it is possible that HD may appear following LCH.

Acknowledgments

The present study was supported by grants from the Tianjin Municipal Health Bureau of Science and Technology Fund (2014KZ021).

References